PPT-Glecaprevir - Pibrentasvir

in HCV GT 1 amp Prior DAA Treatment MAGELLAN1 Part 1 Phase 2 TreatmentExperienced Source Poordad F et al Hepatology 20176638997 Source Poordad F et al Hepatology 20176638997 . Open label. ≥ . 18 years, . HCV genotype 1 to 6. HCV RNA ≥ 1000 IU/mL. eGFR. (MDRD) < 30 mL/min. Treatment-naïve or treatment-experienced with IFN/PEG-IFN ± RBV or SOF + RBV ± PEG-IFN. Compensated cirrhosis allowed. Open label. ≥ . 18 years. HCV genotype 4, 5 or 6. BMI ≥ 18 kg/m. 2. Treatment-naïve or treatment-experienced with IFN or PEG-IFN . +.  RBV or SOF + RBV . +.  PEG-IFN. No cirrhosis **. Creatinine clearance ≥ 50 mL/min. Open label. ≥ . 18 years, . HCV genotype 1 to 6. HCV RNA ≥ 1000 IU/mL. Treatment-naïve or treatment-experienced with IFN/PEG-IFN . +.  RBV or SOF + RBV . +.  PEG-IFN (naïve if genotype 3). HIV co-infection. Next Generation Direct-Acting Antivirals . Geographic Distribution of Enrolled Patients. HCV RNA ≥ 1000 IU/mL. Treatment-naïve or treatment-experienced with IFN or PEG-IFN . .  RBV or SOF RBV ± PEG-IFN. Compensated . cirrhosis *. No HBV or HIV co-infection. Design. W12. EXPEDITION-1 . 18-70 years. Naïve . or failure to. PEG-IFN RBV. HCV RNA > 10 000 IU. /ml. No cirrhosis . No . HBV or HIV. coinfection. SURVEYOR-II study – Part 2: . glecaprevir. . pibrentasvir. in . genotypes 2 or 3 – Phase II . 18 years. BMI ≥ 18 kg/m. 2. HCV genotype 2, 4, 5 or 6. HCV RNA > 1000 IU/ml. Treatment-naïve or treatment-experienced with IFN/PEG-IFN . .  RBV . or SOF RBV . .  PEG-IFN. No cirrhosis *. No HBV or HIV co-infection. 18-70 years. HCV genotype 1 or 3. Naïve or failure to. PEG-IFN RBV. No prior DAA. HCV RNA > 10 000 IU. /ml. Compensated cirrhosis * with Child-Pugh score ≤ 6. Creatinine. . clearnce. > 50 . ≥ 18 years. HCV genotype 3. Treatment-naïve . HCV RNA > 1 000 IU/mL. No cirrhosis **. No HBV co-infection. No HIV co-infection. ENDURANCE-3 Study: . glecaprevir. /. pibrentasvir. . vs SOF DCV in genotype 3 without cirrhosis. Kristen M. Marks, MD. Assistant Professor. Weill Cornell Medical College . New York, New York. Financial Relationships With Commercial Entities. Dr Marks was awarded research grants, paid to her institution, from Bristol-Myers Squibb, Gilead Sciences, .